The human T-cell leukemia virus type 1 (HTLV-1), identified as the first human oncogenic
retrovirus 30 years ago, is not an ubiquitous virus. HTLV-1 is present throughout the world …

Adult T-cell leukemia (ATL) is an aggressive T-cell malignancy caused by human T-cell
leukemia virus type 1 (HTLV-1) that develops through a multistep carcinogenesis process …

BACKGROUND Access to a safe, adequate blood supply has proven challenging in sub‐
Saharan Africa, where systemic deficiencies spanning policy, collections, testing, and …

Human T-lymphotropic virus type 1 (HTLV-1) is the causative agent of adult T-cell leukemia
and HTLV-1-associated myelopathy/tropical spastic paraparesis. The HTLV-1 transactivator …

Human T-lymphotropic virus type 1 (HTLV-1) infection may cause serious disease, while
pathogenicity of HTLV-2 is less certain. There are no screening or surveillance programs for …

Natural selection signatures across Japanese subpopulations are under-explored. Here we
conducted genome-wide selection scans with 622,926 single nucleotide polymorphisms for …

Introduction Most T cell receptor (TCR) Vβ chain-expressing T cell lymphomas (TCL)
including those caused by Human T cell leukaemia virus type-1 (HTLV-1) have poor …

HTLV-1 uveitis (HU) is the third clinical entity to be designated as an HTLV-1-associated
disease. Although HU is considered to be the second-most frequent HTLV-1-associated …

Introduction The Human T-lymphotropic virus type 1 (HTLV-1) was the first described human
retrovirus. It is currently estimated that around 5 to 10 million people worldwide are infected …

There is a growing understanding that several infectious agents are acquired in early life
and this is the reason why available vaccines target the new born, infants, and adolescents …